Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & Administrative
Others
Ratios

Odyssey Health (ODYY) Research & Development (2021)

Odyssey Health has reported Research & Development over the past 1 years, most recently at $1.0 million for Q3 2021.

  • Quarterly results put Research & Development at $1.0 million for Q3 2021, changed N/A from a year ago — trailing twelve months through Jul 2021 was $1.6 million (changed N/A YoY), and the annual figure for FY2024 was $55166.0, down 67.55%.
  • Research & Development for Q3 2021 was $1.0 million at Odyssey Health, up from $565764.0 in the prior quarter.
  • Over the last five years, Research & Development for ODYY hit a ceiling of $1.0 million in Q3 2021 and a floor of $42619.0 in Q1 2021.